Zelira Therapeutics Ltd has released a press release.
Phase 1 Opioid Reduction Clinical Trial Fully Enrolled
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Zelira Meets Primary Endpoints for Insomnia Trial
- Zelira Successfully Completes Capital Raising of $4.6M
- December 2019 Quarterly Report
- Zelira to Collaborate with the Parkinsons Foundation
- Zelira Therapeutics expands HOPE distribution in the U.S.A
Later from Zelira Therapeutics
- Appendix 4D & FY20 Interim Financial Report
- Insomnia Trial Meets Primary and Secondary Endpoints
- March 2020 Quarterly Report
- TasAlk to Manufacture Zeliras Insomnia and HOPE products
- Zelira Phase 1 Chronic Pain Trial Meets Clinical Endpoints
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics